DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU

Information source: Stanford University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Classical Phenylketonuria(PKU)

Phase: Phase 3

Status: Withdrawn

Sponsored by: Stanford University

Official(s) and/or principal investigator(s):
Gregory Enns, MD, Principal Investigator, Affiliation: Stanford University


This study is an independent sub-study of the protocol titled PKU-016: A double-blind, placebo-controlled, randomized study to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuro-psychiatric symptoms in subjects with phenylketonuria (PKU ASCEND). The primary objective of this study is to determine oxidative stress in patients with classical phenylketonuria (PKU) enrolled in PKU-016, using a brain scan (called an HMPAO SPECT) at baseline and 26 weeks, and blood redox biomarkers.

Clinical Details

Official title: The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical Phenylketonuria

Study design: Time Perspective: Prospective

Primary outcome: Determine in vivo redox status in patients with classical phenylketonuria

Secondary outcome:

Compare redox status with neuropsychological and neuro-cognitive symptoms

Explore the utility of other blood redox biomarkers


Minimum age: 8 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: Sub-study Inclusion criteria same as main study:

- ≥ 8 years of age

- Confirmed diagnosis of PKU

- Willing to continue current diet (typical diet for the 3 months prior to study

entry)unchanged while participating in the study

- Willing and able to provide written, signed informed consent or in the case of

subjects under the age of 18, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures

- Sexually active subjects must be willing to use an acceptable method of contraception

while participating in the study and for at least 30 days following the last dose of sapropterin dihydrochloride

- Females of childbearing potential must have a negative pregnancy test at screening

and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or have had total hysterectomy

- Willing and able to comply with all study procedures

Exclusion Criteria: All other sub-study Exclusion criteria same as main study:

- Has known hypersensitivity to sapropterin dihydrochloride or its excipients

- Subject breastfeeding at screening or planning to become pregnant (subject or

partner) at any time during the study

- Use of any investigational product or investigational medical device within 30 days

prior to screening, or requirement for any investigational agent prior to the completion of all scheduled study assessments

- Received sapropterin dihydrochloride within 16 weeks of randomization • Have

initiated or adjusted medication for treatment of ADHD, depression, or anxiety ≤ 8 weeks prior to randomization

- Taking medication known to inhibit folate synthesis (eg, methotrexate)

- Any condition requiring treatment with levodopa or any PDE-5 inhibitor

- Concurrent disease or condition that would interfere with study participation,

compliance or safety as determined by the Investigator

- Any condition that, in the view of the Investigator, places the subject at high risk

of poor treatment compliance or not completing the study

Locations and Contacts

Additional Information

Related publications:

Atkuri KR, Cowan TM, Kwan T, Ng A, Herzenberg LA, Herzenberg LA, Enns GM. Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3941-5. doi: 10.1073/pnas.0813409106. Epub 2009 Feb 17.

Christ SE, Huijbregts SC, de Sonneville LM, White DA. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol Genet Metab. 2010;99 Suppl 1:S22-32. doi: 10.1016/j.ymgme.2009.10.007. Review.

Fernandes CG, Leipnitz G, Seminotti B, Amaral AU, Zanatta A, Vargas CR, Dutra Filho CS, Wajner M. Experimental evidence that phenylalanine provokes oxidative stress in hippocampus and cerebral cortex of developing rats. Cell Mol Neurobiol. 2010 Mar;30(2):317-26. doi: 10.1007/s10571-009-9455-6. Epub 2009 Sep 23.

Jacquier-Sarlin MR, Polla BS, Slosman DO. Oxido-reductive state: the major determinant for cellular retention of technetium-99m-HMPAO. J Nucl Med. 1996 Aug;37(8):1413-6.

Sasaki T, Senda M. Technetium-99m-meso-HMPAO as a potential agent to image cerebral glutathione content. J Nucl Med. 1997 Jul;38(7):1125-9.

Sirtori LR, Dutra-Filho CS, Fitarelli D, Sitta A, Haeser A, Barschak AG, Wajner M, Coelho DM, Llesuy S, Belló-Klein A, Giugliani R, Deon M, Vargas CR. Oxidative stress in patients with phenylketonuria. Biochim Biophys Acta. 2005 Apr 15;1740(1):68-73. Epub 2005 Feb 25.

Sitta A, Barschak AG, Deon M, Terroso T, Pires R, Giugliani R, Dutra-Filho CS, Wajner M, Vargas CR. Investigation of oxidative stress parameters in treated phenylketonuric patients. Metab Brain Dis. 2006 Dec;21(4):287-96. Epub 2006 Dec 5.

Sitta A, Manfredini V, Biasi L, Treméa R, Schwartz IV, Wajner M, Vargas CR. Evidence that DNA damage is associated to phenylalanine blood levels in leukocytes from phenylketonuric patients. Mutat Res. 2009 Sep-Oct;679(1-2):13-6. doi: 10.1016/j.mrgentox.2009.07.013. Epub 2009 Aug 7.

Starting date: July 2012
Last updated: April 21, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017